Source: Science and Technology Daily
Amyotrophic lateral sclerosis (ALS), also known as motor neuronal disease, is characterized by the presence of abnormal forms of proteins such as superoxide dismutase 1 (SOD1), which accumulate in neurons and then degenerate to death. Researchers at the University of Zurich Institute of Regenerative Medicine, Tobias Velt, have extracted a human antibody from a healthy group of adults who recognize the superoxide dismutation in spinal cord tissue of patients with amyotrophic lateral sclerosis. Enzyme 1 is abnormal. When administered to an animal model of amyotrophic lateral sclerosis, the antibody may delay the onset of atherosclerosis, extend the survival time of the animal, reduce neuronal degradation, and superoxide dismutase 1 aggregate aggregation. These results indicate that this human antibody has a potential value in the treatment of amyotrophic lateral sclerosis, including an excessive folding of superoxide dismutase 1.
(Article Source: Science and Technology Daily)